Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TMB-H + PD-L1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TMB-H + PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	TMB-H + PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4
TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4